Informed that McKinsey had consulted for the FDA while advising Purdue, Dr. Andrew Kolodny, a senior scientist and co-director of opioid policy research at Brandeis University, expressed surprise. “It is a very obvious conflict of interest,” he said in an interview. “That never should have been allowed, never should have happened.”
